Research Article
The Correlation of PPARα Activity and Cardiomyocyte Metabolism and Structure in Idiopathic Dilated Cardiomyopathy during Heart Failure Progression
| | Control () LVEF > 60% | Group (I) () LVEF 50–45% | Group (II) () LVEF 44–30% | Group (III) () LVEF < 30% |
| Age (y) | 32.6 ± 10.8 | 34 ± 9.39 | 38.8 ± 7.87 | 41.13 ± 11.83 | Men/women () | 5/1 | 8/2 | 12/3 | 11/4 | NYHA class | — | 1.22 ± 0.44 | 1.6 ± 0.57 | 2.10 ± 0.47 | BMI | 22.05 ± 0.92 | 21.7 ± 1.43 | 26.58 ± 2.89 | 25.35 ± 3.88 | LV EF [%] | 63 ± 4 | 47.77 ± 2.81 | 35.80 ± 3.42 | 22.33 ± 4.06 | LV EDD [mm] | 51.34 ± 3.74 | 53.44 ± 1.74 | 65.13 ± 7.38 | 71.53 ± 6.65 | LV ESD [mm] | 30 ± 1.4 | 34.55 ± 4.74 | 47.73 ± 8.75 | 60.13 ± 5.46 | ESV [mL] | 45 ± 8 | 52 ± 4.2 | 124.2 ± 44.76 | 188.93 ± 49.25 | EDV [mL] | 102 ± 13.2 | 105 ± 24.8 | 182.86 ± 57.9 | 241.8 ± 79.15 | NT-proBNP [pg/mL] | 64.4 ± 1.4 | 78.61 ± 1.3 | 999.8 ± 1625.1 | 1709.6 ± 2314.3 | Creatinine [µmol/L] | 68.9 ± 10.2 | 72.01 ± 10.5 | 72.22 ± 13.09 | 76.46 ± 12.5 | Glucose [mmol/L] | 5 ± 0.40 | 5.03 ± 0.45 | 5.02 ± 0.40 | 5.51 ± 0.91 | Cholesterol [mmol/L] | 3.3 ± 1.42 | 3.33 ± 1.97 | 5.13 ± 0.58 | 4.99 ± 1.55 | TG [mmol/L] | 1.45 ± 0.21 | 0.85 ± 0.74 | 1.62 ± 0.77 | 1.53 ± 0.86 | HDL [mmol/L] | 1.2 ± 0.81 | 1.05 ± 0.84 | 1.39 ± 3.14 | 1.40 ± 0.56 | LDL [mmol/L] | 2.12 ± 0.50 | 2.01 ± 1.39 | 3.14 ± 0.60 | 2.45 ± 1.34 | Diuretics | — | 1 | 8 | 14 | Digitalis | — | 1 | 4 | 9 | ACE inhibitors | — | 2 | 3 | 3 | β-blockers | — | 3 | 6 | 5 |
|
|